Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 30/11/2023

    Taking antibiotics back in time

    University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/taking-antibiotics-back-time
  • Press release - 06/11/2023

    Improving the efficacy of cancer immunotherapy with modified CAR-T cells

    CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments are unsuccessful. A limiting factor of this very effective and safe therapy is that the cells used in the process quickly reach a state of exhaustion. Researchers at the University of Freiburg have now been able to prevent this exhaustion and thus significantly improve the effect of the therapy in a preclinical animal model.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/improving-efficacy-cancer-immunotherapy-modified-car-t-cells
  • Macrophages interacting with cytomegaloviruses - 22/02/2022 Graphik_CMV_Makrophagen_Teaser.jpg

    Cytomegaloviruses subvert macrophage identity

    Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.

    https://biopro-v9-test-gi.xanium.io/en/article/news/cytomegaloviruses-subvert-macrophage-identity
  • Press release - 16/11/2021

    Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation

    Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
  • Press release - 02/09/2021

    Award-winning science: Cancer-promoting metabolic pathways as targets of new therapies

    Christiane Opitz, scientist at the German Cancer Research Center, is being awarded this year's Ita Askonas Prize of the European Federation of Immunological Societies. Opitz has discovered how tumor cells use certain metabolites to protect themselves against the immune system. Her research findings may provide important clues for the development of new therapeutic concepts.

    https://biopro-v9-test-gi.xanium.io/en/article/press-release/award-winning-science-cancer-promoting-metabolic-pathways-targets-new-therapies
  • Signal mechanisms in inflammatory processes - 18/05/2021 aktivierte-makrophagen.jpg

    Newly discovered substances activate the inflammasome in macrophages

    Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

    https://biopro-v9-test-gi.xanium.io/en/article/news/newly-discovered-substances-activate-inflammasome-macrophages
  • Intestinal peptide heals lung - 14/10/2020 Die Immuntherapie (ICI)  aktiviert Effektor-T-Zellen  und reduziert auf der anderen Seite regulatorische T-zellen, um den Tumor zu besiegen (schwarze Zellen). Die durch die Immuntherapie ausgelöste Lungenentzündung wird mit Steroidtherapie (Cortison) oder mit inhaliertem VIP (vasoaktives intestinales Peptid) behandelt. Unter VIP kommt es zur Dämpfung der Entzündung.

    Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

    If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

    https://biopro-v9-test-gi.xanium.io/en/article/news/inhalation-intestinal-hormone-vip-helps-against-immunotherapy-induced-pneumonia
  • Affimed GmbH - 01/07/2020 Schematische Darstellung der Kommunikation zwischen den Zellen der angeborenen und erworbenen Immunität. „innate cell engager“ aktivieren NK-Zellen und Makrophagen, die wiederum tumorspezifische T-Zellen stimulieren.

    "Innate cell engager" fighting against cancer

    In the fight against tumour cells, d Affimed GmbH from Heidelberg relies entirely on the weapons of the innate immune system. Affimed has developed special innate cell engagers, which are bispecific antibodies that recognise tumour cells and bring them together with natural killer cells and macrophages of the innate immune system, which then kill the tumour cells. Clinical trials using the AFM13 molecule are ongoing.

    https://biopro-v9-test-gi.xanium.io/en/article/news/innate-cell-engager-fighting-against-cancer
  • Dossier - 06/12/2019 Staphylococcus-lugdunensis-Antibiotikum.jpg

    Microbiome: human health is closely connected with our microbial communities

    People have 1.3 times more microorganisms than body cells. This microbial community influences how we digest our food, how active our immune system is, as well as whether we tend to be more anxious or curious. A number of diseases have also been shown to be associated with a disturbed microbiome. Researchers still have a long way to go before the knowledge acquired can be used for developing therapies.

    https://biopro-v9-test-gi.xanium.io/en/article/dossier/microbiome-human-health-closely-connected-with-microbial-communities
  • Article - 22/10/2019 AVA LifeScience-Gründer: Ulrich Birsner, Marc Kessemeier, Dr. Marcus Dühren-von Minden (von links nach rechts).

    Using CAR T cells for treating cancer

    After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.

    https://biopro-v9-test-gi.xanium.io/en/article/news/using-car-t-cells-for-treating-cancer
  • Dossier - 14/06/2016 Schematic showing the defence chain of a prokaryote with CRISPR/Cas - integration of a phage genome into the CRISPR array and an infection of another phage whose genome is already "known" in the array. The new piece of DNA is immediately destroyed by the CRISPR/Cas complex.

    CRISPR/Cas – genome editing is becoming increasingly popular

    The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases.

    https://biopro-v9-test-gi.xanium.io/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
  • Dossier - 09/09/2013 Immunofluorescence image of two dendritic mouse cells with MHC complexes (labelled with red-fluorescent antibodies) on their surface.

    New trends in the field of immunology

    B- and T- lymphocytes along with macrophages have long been regarded as the most important cells of the human immune system and have been a major focus of research. This has now changed and it is now the dendritic cells that are regarded as the major components of the adaptive immune system. Research into innate immune defence mechanisms has become more important due to the discovery of the role of Toll-like receptors as first-line of defence.

    https://biopro-v9-test-gi.xanium.io/en/article/dossier/new-trends-in-the-field-of-immunology
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://biopro-v9-test-gi.xanium.io/en/search